Olmesartan is a potent ARB that provides effective blood pressure reduction with once-daily dosing. It is available in multiple fixed-dose combinations. Notably, it carries a unique FDA warning for sprue-like enteropathy, an adverse effect not typically seen with other ARBs.
Evidence rating strong. Most-documented uses: potent blood pressure reduction, effective once-daily dosing, available in combination with amlodipine and/or hctz. 10 sources indexed (2016–2024), with 2 interaction records on file.
The science
How it works, mechanistically.
Core mechanism
Administered as the prodrug olmesartan medoxomil, which is rapidly hydrolyzed to the active olmesartan during absorption. Selectively blocks the AT1 receptor with high binding affinity. Prevents angiotensin II-mediated vasoconstriction, aldosterone release, and cardiac hypertrophy.3,1
Class
Angiotensin II Receptor Blocker (ARB)
Dosing
Dosing & protocol.
Common range
20–40 mg once daily (as prescribed by your physician)
Recommended form
Oral tablet
Can be taken with or without food; prodrug rapidly converted to active form during absorption
Depletions
What it depletes.
Nutrients this medication can lower over time, and what to replace.
Zinc
Mild
ARB therapy can modestly increase urinary zinc losses in some users, though typically less than ACE inhibitors.
Olmesartan blocks the angiotensin II type 1 receptor, suppressing aldosterone and reducing renal potassium excretion. Adding a potassium supplement can produce hyperkalemia, especially in older adults, patients with kidney disease or diabetes, or those also taking NSAIDs, potassium-sparing diuretics, or trimethoprim. Hyperkalemia can be silent until it triggers arrhythmias.
Recommendation: Avoid potassium supplements while taking olmesartan unless a deficiency has been confirmed by your prescriber. If both are needed, get potassium checked within 1-2 weeks of starting and after any dose change. Skip potassium-based salt substitutes.
Olmesartan blocks the AT1 receptor, reduces sodium reabsorption, and increases lithium retention by the kidney. Multiple case reports with ARBs describe lithium toxicity developing weeks after starting therapy, sometimes at previously safe lithium doses. Lithium Orotate doses are smaller but use the same renal pathway and the therapeutic window is narrow.
Recommendation: Avoid Lithium Orotate while taking olmesartan. If you must combine them, keep the dose low, stay well hydrated, and ask your prescriber to check serum lithium after 1-2 weeks. Hold the supplement during vomiting, diarrhea, or fever.
Raja R, Kumari S, Umer Khan M et al.. Antihypertensive Effects of Sacubitril/Valsartan Versus Olmesartan: An Updated Systemic Review and Meta-Analysis of Randomized Controlled Trials. Cureus. 2023
Kumar L, Khuwaja S, Kumar A et al.. Exploring the Effectiveness and Safety of Azilsartan-Medoxomil/Chlorthalidone Versus Olmesartan-Medoxomil/Hydrochlorothiazide in Hypertensive Patients: A Meta-Analysis. Cureus. 2023
Han Y, Zhou Y, Na J et al.. Efficacy and Safety Comparative of Sacubitril/Valsartan vs. Olmesartan in the Treatment of hypertension: A Meta-analysis of RCTs. American journal of hypertension. 2023
Burbure N, Lebwohl B, Arguelles-Grande C et al.. Olmesartan-associated sprue-like enteropathy: a systematic review with emphasis on histopathology. Human pathology. 2016
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Olmesartan in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack